Expanding individualized therapeutic options via genoproteomics

Zhan, Dongdong; Zheng, Nairen; Cheng, Fang; Tang, Qihe; Liu, Xiangqian; Wang, Juanfei; Wang, Yushen; Liua, Haibo; Li, Xinliang; Su, Juming; Zhong, Xi; Bu, Qing; Cheng, Yueming; Wang, Yi; Qin, Jun

doi:10.1016/j.canlet.2023.216123

Cited by 4 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include mesenchymal epithelial transition, Wnt, Hedgehog or tumor growth factor, to name a few. 82 Table 1 summarizes the total number of clinical trials in different phases for gastrointestinal tract tumors. Table 2 summarizes the results of just a few relevant clinical trials.…”

Section: Large Bowelmentioning

confidence: 99%

A Review and Update on Therapy of Gastrointestinal Tract Tumors: From the Bench to Clinical Practice

Fernández-Aceñero,

Hernández,

del Arco

2024

J Clin Transl Pathol

View full text Add to dashboard Cite

Gastrointestinal tract tumors, i.e., esophageal, gastric, small, and large bowel carcinomas, are some of the most frequent malignant neoplasms. The landscape of these neoplasms varies significantly. Although the incidence of esophageal carcinoma seems to be decreasing, gastroesophageal junction tumors are on the rise. The incidence of antral gastric carcinoma of the tubular type also seems to be decreasing,

show abstract

Section: Large Bowelmentioning

confidence: 99%

A Review and Update on Therapy of Gastrointestinal Tract Tumors: From the Bench to Clinical Practice

Fernández-Aceñero,

Hernández,

del Arco

2024

J Clin Transl Pathol

View full text Add to dashboard Cite

show abstract

“…While subtyping based on genomic and transcriptomic analyses has greatly improved our understanding of SCLC, the resulting subtypes correlated poorly with clinical outcomes. In contrast, subtyping with proteomics had revealed its exceptional clinical potential for more accurate predication of prognosis, chemo-sensitivity, and treatment targets for myriad cancers including stomach [19,20], liver [21,22], ovarian carcinoma [23] , colorectal cancer [24], and NSCLC [25,26,27,28,29]. Here, we report a proteomic subtyping model derived from a discovery dataset containing 75 surgically resected formalin-fixed, paraffin-embedded (FFPE) samples.…”

Section: Introductionmentioning

confidence: 99%

Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer

Huo,

Duan,

Zhan

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is a highly malignant and heterogeneous cancer with limited therapeutic options and prognosis prediction models. Here, we analyzed formalin-fixed, paraffin-embedded (FFPE) samples of surgical resections by proteomic profiling, and stratified SCLC into three proteomic subtypes (S-I, S-II, and S-III) with distinct clinical outcomes and chemotherapy responses. The proteomic subtyping was an independent prognostic factor and performed better than current TNM or Veterans Administration Lung Study Group (VALG) staging methods. The subtyping results could be further validated using FFPE biopsy samples from an independent center, extending the analysis to both surgical and biopsy samples. The signatures of the S-II subtype in particular suggest potential benefits from immunotherapy. Differentially overexpressed proteins in S-III, the worst prognostic subtype, allowed us to nominate potential therapeutic targets, indicating that patient selection may bring new hope for previously failed clinical trials. Finally, analysis of an independent cohort of SCLC patients who had received immunotherapy validated the prediction that the S-II patients had better Progression Free Survival (PFS) and Overall Survival (OS) after first-line immunotherapy. Collectively, our study provides the rationale for future clinical investigations to validate the current findings for more accurate prognosis prediction and precise treatments.

show abstract

Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia

Yan,

Wang,

Wang

et al. 2024

Cancer Letters

View full text Add to dashboard Cite

Expanding individualized therapeutic options via genoproteomics

Cited by 4 publications

References 64 publications

A Review and Update on Therapy of Gastrointestinal Tract Tumors: From the Bench to Clinical Practice

A Review and Update on Therapy of Gastrointestinal Tract Tumors: From the Bench to Clinical Practice

Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer

Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia

Contact Info

Product

Resources

About